Overview
SLXN market data
Price History
SLXN price chart
Valuation & Profitability
- P/E (TTM)
- — Trailing twelve-month price-to-earnings ratio. Higher means the market is pricing in more growth. Negative or missing when earnings are negative.
- Forward P/E
- — P/E based on consensus forward EPS estimates. Lower versus trailing implies expected earnings growth.
- EPS (TTM)
- -$89.60 Diluted earnings per share over the trailing twelve months.
- Beta
- -0.27 Volatility relative to the index. 1.00 equals market, above 1 amplifies the broad-market move, below 1 dampens it.
- Dividend Yield
- — Annual dividend per share divided by current price. Zero or blank when the company does not pay a dividend.
- Profit Margin
- — Net income divided by revenue. Comparable within a sector, less so across sectors.
- 52w range
- $2.20 – $223.60 Lowest and highest closing prices over the past 52 weeks.
- Analyst Target
- — Mean of sell-side analyst 12-month price targets. Use as a sentiment gauge; targets are biased upward in aggregate.
Display-only. Refreshed once per symbol per 24 hours · source Twelve Data /statistics · market cap $1.7 · P/B 2.31.
Company News
Silexion Therapeutics shares are trading lower. The company announced initiation of its Phase 2/3 clinical trial of SIL204, lead siRNA product candidate, at TASMC.Benzinga · Jul 29, 2026, 2:09 PM
Silexion Therapeutics Receives Approval From Germany's Federal Institute For Drugs And Medical Devices To Start Its Planned Phase 2/3 Clinical Study Of SIL204 In Participants With Locally Advanced Pancreatic CancerBenzinga · Jun 23, 2026, 12:50 PM
Trading Halt: Halt status updated at 8:55:00 AM ET: Quotation Resumption: News and Resumption TimesBenzinga · May 29, 2026, 12:55 PM
Trading Halt: Halted at 7:50:00 p.m. ET - Trading Halt: Halt News PendingBenzinga · May 28, 2026, 11:50 PM
Silexion Therapeutics shares are trading lower after the company announced a 1-for-10 reverse share split.Benzinga · May 26, 2026, 1:03 PM
Silexion Therapeutics Announces 1-For-10 Reverse Share Split Of Ordinary Shares, Effective May 28Benzinga · May 26, 2026, 12:33 PM
Nasdaq Gains 100 Points; Target Earnings Top ViewsBenzinga · May 20, 2026, 1:50 PM
Silexion Therapeutics Q1 EPS $(0.85) Beats $(1.29) EstimateBenzinga · May 15, 2026, 10:58 PM
Dow Tumbles 500 Points; NY Manufacturing Activity Surges In MayBenzinga · May 15, 2026, 2:00 PM
Silexion Therapeutics Announces Exercise Of Warrants To Purchase 1,995,092 Shares At $0.50 Per ShareBenzinga · May 15, 2026, 12:40 PM